Skip to main content
TipRanks
Go Ultimate75% OFF

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

2 Followers
IN:JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd.

(NSE:JAGSNPHARM)

Select Model
Rating:69Neutral
Price Target:INR 229.00â–²(9.20% Upside)
Action:downgraded
Date:11/19/26

Strong financial fundamentals are the primary support for the score, led by the conservative balance sheet and solid cash generation. This is offset by weak technical momentum and a relatively high P/E ratio despite the modest dividend yield.

Positive Factors
Revenue GrowthThe sharp 2026 revenue re-acceleration indicates strong renewed demand for the company’s branded formulations and improved commercial momentum. If sustained, higher sales can expand operating scale, support reinvestment across therapeutic areas, and strengthen the company’s domestic market position over the next several quarters.
Negative Factors
Earnings DeclineThe decline in net income despite substantially higher revenue shows that top-line growth has not yet translated consistently into bottom-line expansion. Continued earnings pressure could limit retained capital, weaken the quality of reported growth, and make medium-term profit outcomes less predictable.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%IN:JAGSNPHARM+6.71%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 11.37B
Dividend Yield
1.91%
Average Volume (3M)
12.57K
Price to Earnings (P/E)
30.7
Beta (1Y)
0.75
Revenue Growth
11.71%
EPS Growth
-26.92%
Country
India
Employees
1,297
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spa...

How the Company Makes Money

Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/dis...

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Strong profitability, a conservative balance sheet, and consistently positive cash flow support a robust financial profile. Growth, margins, returns, and operating cash flow have moderated or shown volatility recently.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.16B2.87B2.69B2.09B2.37B2.18B
Gross Profit1.45B1.83B1.72B652.59M1.44B1.28B
EBITDA656.32M679.90M510.71M323.46M362.61M284.29M
Net Income451.90M430.82M553.61M224.63M267.21M188.55M
Balance Sheet
Total Assets3.18B3.17B2.78B2.17B1.95B1.68B
Cash, Cash Equivalents and Short-Term Investments1.15B1.06B1.29B1.48B1.15B472.77M
Total Debt92.16M81.65M92.39M89.41M60.01M52.47M
Total Liabilities739.81M405.05M383.10M296.76M360.56M375.99M
Stockholders Equity2.41B2.76B2.40B1.87B1.59B1.31B
Cash Flow
Free Cash Flow0466.64M549.52M349.18M463.37M51.31M
Operating Cash Flow0468.12M553.00M351.66M466.54M55.98M
Investing Cash Flow0-356.49M-451.47M-245.48M-576.71M-257.79M
Financing Cash Flow0-121.49M-116.98M-89.11M-4.57M-175.52M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price209.70

Price Trends

50DMA225.31Negative
100DMA226.83Negative
200DMA207.85Positive

Market Momentum

MACD-3.47Positive
RSI37.23Neutral
STOCH4.47Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 209.70 is below the 20-day moving average (MA) of 217.24, below the 50-day MA of 225.31, and above the 200-day MA of 207.85, indicating a neutral trend. The MACD of -3.47 indicates Positive momentum. The RSI at 37.23 is Neutral, neither overbought nor oversold. The STOCH value of 4.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:JAGSNPHARM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SYNCOMFIN:SYNCOMF79OutperformINR 20.74B24.26―0.45%0.44%48.60%
IN:VENUSREMIN:VENUSREM74OutperformINR 19.37B15.98―0.69%20.22%73.03%
IN:JAGSNPHARMIN:JAGSNPHARM69NeutralINR 13.99B30.72―1.91%11.71%-26.92%
IN:SAKARIN:SAKAR68NeutralINR 22.16B52.40――47.99%117.99%
IN:LINCOLNIN:LINCOLN67NeutralINR 10.29B10.63―0.35%14.25%21.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:INDSWFTLABIN:INDSWFTLAB51NeutralINR 29.21B34.50――66.39%-72.31%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%IN:JAGSNPHARMIN:INDSWFTLABIN:LINCOLNIN:SAKARIN:SYNCOMFIN:VENUSREMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JAGSNPHARM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JAGSNPHARMJagsonpal Pharmaceuticals Ltd.209.7011.825.97%
IN:INDSWFTLABInd-Swift Laboratories Ltd.330.20229.50227.90%
IN:LINCOLNLincoln Pharmaceuticals Ltd511.90-16.05-3.04%
IN:SAKARSakar Healthcare Ltd976.20603.80162.14%
IN:SYNCOMFSyncom Formulation (India) Ltd.22.096.3139.97%
IN:VENUSREMVenus Remedies Limited1500.75802.65114.98%

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Sets Virtual AGM and Dividend Record Date for September 2026

Aug 27, 2026

Jagsonpal Pharmaceuticals Limited has scheduled its 47th Annual General Meeting for September 18, 2026, to be conducted via video conferencing and other audio-visual means in line with regulatory guidance. The company has circulated the AGM notice an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026